Skip to content

Contact +44 (0) 20 7060 7474 email us

Cancer

Currently Druggable in Breast Cancer

A Drug Target Competitive Analysis

Publication Date August 2008
Publisher Bioseeker
Product Type Report
Pages 316
ISBN Number not applicable
Product Code BSK00175

Price

£1,750.00
approximately: $2,681 | €1,950

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

Executive Summary

This report aims to analyze the current and future potential of breast cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type.

This report is written for you to identify your competition and understand which targeting strategies are at work within breast cancer drug development. It allows you to pin-point which competitors drugs' clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you.

Drug targets are the critical link between drugs and their role in the treatment of medical disorders. BioSeeker has surveyed the breast cancer field and identified 148 drug targets belonging to 243 drugs. This report, Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of breast cancer drugs.

In the report, BioSeeker reports on 130 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 243 breast cancer drugs. The highest degree of distinctiveness among the cancer drugs is achieved by sorting each of them according to drug target mix, compound type and therapy strategy. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.

To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of breast drugs. No less than 311 protein-protein interactions were recognized among and between 114 of the 143 included breast cancer drug targets.

Why You Should Own Your Own Copy of this Report:

  • 310+ pages, with more than 60 different tables and figures. Includes more than 1,000 active links to drug target related resources on the Internet
  • A 243 breast cancer drugs analysis, under development by 152 investigators
  • 148 unique, in-depth, drug target validating profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other breast cancer drug targets, pursued cancer indications, drugs under development, presence in the Cancer Genome Project etc.
  • A unique drug target combination breakdown of breast cancer drugs into major therapy strategies
  • Unique drug-protein target interactome- and protein-protein interactome of drug targets analysis
  • Pathway profiling of breast cancer drug targets
  • Pin-point which competitor drugs' clinical out-come may have bearing on your own drug development
  • Who are working on sequels to blockbuster drugs?
  • Locate white-spots in the competitive landscape, giving you little or no competition
  • In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.

Contents

  • Executive Summary
  • 2 About Cancer Highlights
  • 3 Methodologies
  • 4 Table of Contents
    • 4.1 List of Figures
    • 4.2 List of Tables
  • 5 How to Use this Report
  • 6 Breast Cancer Target Localization
  • 7 The Cancer Genome Project and Breast Cancer Targets
    • 7.1 Breast Cancer Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
  • 8 Protein Expression Profiles of Breast Cancer Drug Targets in Human
    • 8.1 Expression in Normal Tissues and Cancer Tissues
    • 8.2 Expression in Human Cancer Cell Lines and Primary Cells
  • 9 Pathway Analysis of Breast Cancer Drugs
  • 10 Protein-Protein Interactions Among Identified Breast Cancer Targets
  • 11 Available Biological Structure Data on Breast Cancer Targets
  • 12 Drug Target Profiles of Breast Cancer Drugs
    • 12.1.1 Catalytic Activity
    • 12.1.2 Cell Adhesion Molecule Activity
    • 12.1.3 Chaperone Activity
    • 12.1.4 Chemokine Activity
    • 12.1.5 Complement Activity
    • 12.1.6 Cysteine-Type Peptidase Activity
    • 12.1.7 Cytokine Activity
    • 12.1.8 DNA Binding
    • 12.1.9 DNA Repair Protein
    • 12.1.10 DNA Topoisomerase Activity
    • 12.1.11 DNA-Directed DNA Polymerase Activity
    • 12.1.12 Glutathione Transferase Activity
    • 12.1.13 G-Protein Coupled Receptor Activity
    • 12.1.14 Growth Factor Activity
    • 12.1.15 Hormone Activity
    • 12.1.16 Kinase Activity
    • 12.1.17 Kinase Binding
    • 12.1.18 Kinase Regulator Activity
    • 12.1.19 Ligand-Dependent Nuclear Receptor Activity
    • 12.1.20 Ligase Activity
    • 12.1.21 Lipid Kinase Activity
    • 12.1.22 Lipid Phosphatase Activity
    • 12.1.23 Metallopeptidase Activity
    • 12.1.24 Molecular Function Unknown
    • 12.1.25 Motor Activity
    • 12.1.26 Oxidoreductase Activity
    • 12.1.27 Protein Binding
    • 12.1.28 Protein Serine/Threonine Kinase Activity
    • 12.1.29 Protein Threonine/Tyrosine Kinase Activity
    • 12.1.30 Protein-Tyrosine Kinase Activity
    • 12.1.31 Receptor Activity
    • 12.1.32 Receptor Binding
    • 12.1.33 Receptor Signaling Complex Scaffold Activity
    • 12.1.34 Receptor Signaling Protein Serine/Threonine Kinase Activity
    • 12.1.35 Serine-Type Peptidase Activity
    • 12.1.36 Structural Constituent of Cytoskeleton
    • 12.1.37 Structural Molecule Activity
    • 12.1.38 Superoxide Dismutase Activity
    • 12.1.39 T Cell Receptor Activity
    • 12.1.40 Transcription Factor Activity
    • 12.1.41 Transcription Regulator Activity
    • 12.1.42 Transferase Activity
    • 12.1.43 Translation Regulator Activity
    • 12.1.44 Transmembrane Receptor Activity
    • 12.1.45 Transmembrane Receptor Protein Tyrosine Kinase Activity
    • 12.1.46 Transporter Activity
  • 13 The Drug-Target Interactome
  • 14 The Progression and Maturity of Breast Cancer Targets
    • 14.1 Target Profiles of Breast Cancer Drugs in Pre-Registration or on the Market
    • 14.2 New and Unique Breast Cancer Targets in Phase III Clinical Development
    • 14.3 New and Unique Breast Cancer Targets in Phase II Clinical Development
    • 14.4 New and Unique Breast Cancer Targets in Phase I Clinical Development
    • 14.5 New and Unique Breast Cancer Targets in Preclinical Development
    • 14.6 Development Profiles of All Breast Cancer Target Combinations
  • 15 Targets by Major Therapy Strategies in Breast Cancer
  • 15.1 Small Molecules
    • 15.1.1 Background
    • 15.1.2 Targets in Breast Cancer
  • 15.2 Peptide/Protein Drugs
    • 15.2.1 Background
    • 15.2.2 Targets in Breast Cancer
  • 15.3 Monoclonal Antibodies and Antibody-Like Structures
    • 15.3.1 Background
    • 15.3.2 Targets in Breast Cancer
  • 15.4 Nucleic Acid Therapies
    • 15.4.1 Background
    • 15.4.2 Targets in Breast Cancer
  • 15.5 Cell and Gene Therapy
    • 15.5.1 Background
    • 15.5.2 Targets in Breast Cancer
  • 15.6 Drug Delivery and Nanotechnology
    • 15.6.1 Background
    • 15.6.2 Targets in Breast Cancer
  • 16 Breast Cancer Targets by Companies
    • 16.1 Australia
    • 16.2 Austria
    • 16.3 Canada
    • 16.4 China
    • 16.5 Cuba
    • 16.6 Denmark
    • 16.7 Finland
    • 16.8 France
    • 16.9 Germany
    • 16.10 India
    • 16.11 Ireland
    • 16.12 Israel
    • 16.13 Italy
    • 16.14 Japan
    • 16.15 Netherlands
    • 16.16 New Zealand
    • 16.17 Norway
    • 16.18 South Korea
    • 16.19 Sweden
    • 16.20 Switzerland
    • 16.21 United Kingdom
    • 16.22 USA
    • 16.23 Non-Industrial Bodies
  • 17 Disclaimer
  • 18 Drug Index
  • 19 Company Index
  • List of Figures
    • Figure 1: Distribution of Compound Types among Breast Cancer Drugs
    • Figure 2: Primary Sub-cellular Localization of Drug Targets
    • Figure 3: Visualization of Protein-Protein Interactions Among Antibody Drug Targets
    • Figure 4: The Drug-Protein Interactome of Breast Cancer Drugs Main Cluster
    • Figure 5: The Drug-Protein Interactome of Breast Cancer Drugs Smaller Clusters
    • Figure 6: Head-to-Head Targeting Interactome of Breast Cancer Drugs
  • List of Tables
    • Table 1: Compound Type Versus Primary and Alternate Localization of Drug Target
    • Table 3: Drug Targets of Breast Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census26
    • Table 4: Available Protein Expression Profiles of Breast Cancer Drug Targets
    • Table 5: Pathway Summary
    • Table 6: Drug Targets without any Identified Assigned Pathways
    • Table 7: Pathway Profile According to BioCarta of Breast Cancer Drug Targets
    • Table 8: Pathway Profile According to KEGG of Breast Cancer Drug Targets
    • Table 9: Breast Cancer Drugs Targeting Major Singaling Pathways
    • Table 10: Protein-Protein Interactions among Breast Cancer Drug Targets
    • Table 11: Number of Available Biological Structures of Breast Cancer Drug Targets
    • Table 12: Overview of Drug Target Profile Themes
    • Table 13: Drug-Protein Interactome Clusters
    • Table 14: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, and the Presence of New Drug ~ Target Mixes by Developmental Stage
    • Table 15: Top 5 Pursued Breast Cancer Targets
    • Table 16: Target Profiles of Breast Cancer Drugs in Pre-Registration or on the Market
    • Table 17: New and Unique Breast Cancer Targets in Phase III Clinical Development
    • Table 18: New and Unique Breast Cancer Targets in Phase II Clinical Development
    • Table 19 New and Unique Breast Cancer Targets in Phase I Clinical Development
    • Table 20: New and Unique Breast Cancer Targets in Preclinical Development
    • Table 21: The Progression, Maturity and Competitive Comparison of Breast Cancer Drug Targets in Development
    • Table 22: Number of Breast Cancer Drug Target Mixes Reported by Line of Therapy
    • Table 23: Number of Head-to-head Competing Small Molecule Drugs for the Treatment of Breast Cancer by Drug Target
    • Table 24: Drug Targets of Small Molecule Drugs in Breast Cancer
    • Table 25: Mechanistic Relationship between Small Molecule Drugs in Breast Cancer
    • Table 26: Drug Targets of Peptide Based Drugs in Breast Cancer
    • Table 27: Drug Targets of Protein Based Drugs in Breast Cancer
    • Table 28: Drug Targets of Monoclonal Antibodies and Antibody-Like Drugs in Breast Cancer
    • Table 29: Drug Targets of Nucleic Acid Therapies in Breast Cancer
    • Table 30: Potential Forms of Cell Therapy
    • Table 31: Vectors in Gene Therapy
    • Table 32: Drug Targets of Cell Therapies in Breast Cancer
    • Table 33: Drug Targets of Gene Therapies in Breast Cancer
    • Table 34: Drug Targets with New Drug Delivery Strategies in Breast Cancer
    • Table 35: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Australia
    • Table 36: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Austria
    • Table 37: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Canada
    • Table 38: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in China
    • Table 39: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Cuba
    • Table 40: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Denmark
    • Table 41: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Finland
    • Table 42: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in France
    • Table 43: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Germany
    • Table 44: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in India
    • Table 45: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Ireland
    • Table 46: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Israel
    • Table 47: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Italy
    • Table 48: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Japan
    • Table 49: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in the Netherlands
    • Table 50: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in New Zealand
    • Table 51: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Norway
    • Table 52: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in South Korea
    • Table 53: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Sweden
    • Table 54: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Switzerland
    • Table 55: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in United Kingdom
    • Table 56: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in USA
    • Table 57: Breast Cancer Drugs with Drug Target Mix and Developmental Projects by Non-Industrial Bodies